Rocket Lab's Financial Ascent Faces a Critical Test

Rocket Lab's FY2025 revenue hit $602M, beating forecasts, but a 6-month delay for its Neutron rocket to late 2026 raises costs and investor concerns.

Rocket Lab USA continues to demonstrate its operational prowess, posting record revenue for fiscal year 2025 that surpassed even the most optimistic analyst forecasts. However, this impressive financial performance is shadowed by significant challenges in its flagship development program, creating a complex narrative for investors.

Operational Momentum and Robust Guidance

The company's reliability was recently showcased by its 83rd successful launch, executed a mere six days after its previous mission. This rapid launch cadence is translating directly into financial results. For FY2025, Rocket Lab reported record revenue of approximately $602 million, representing year-over-year growth of about 38%. The fourth quarter also outperformed Wall Street's expectations, with revenue nearing $180 million and a lower-than-anticipated loss per share.

The forward-looking picture appears financially solid. The company's contractually secured backlog stood at roughly $1.85 billion at the close of Q4. Management indicated that approximately 37% of this backlog is expected to be recognized as revenue within the coming twelve months. For the first quarter of 2026, guidance projects revenue between $185 million and $200 million, a range that sits well above consensus estimates.

The Neutron Delay: A Cloud on the Horizon

Despite the strong performance of its current Electron launch vehicle, the development of the next-generation Neutron rocket presents a persistent concern. Following the discovery of a crack in the first-stage tank during testing, the company's leadership was forced to postpone the rocket's inaugural flight to the fourth quarter of 2026. This six-month delay not only dampens sentiment but is also driving higher research and development expenditures.

Market experts view this as the primary risk factor for the equity. While firms like Cantor Fitzgerald raised their price target to $85, Needham & Company adjusted its target downward to $95. The concern is well-founded: the Neutron is central to the firm's long-term growth strategy, and any further setbacks could severely undermine confidence in the project timeline.

Valuation Concerns and Insider Activity

Amid these mixed signals, company executives have been capitalizing on the elevated share price. In early March, CFO Adam C. Spice and Chief Legal Officer Arjun Kampani sold portions of their holdings. Although these transactions were partly conducted to cover tax obligations or followed pre-arranged trading plans, their collective occurrence has introduced additional supply to the market.

Closing at $72.52 on Friday, the stock is currently valued at 46.6 times its expected sales. Following an advance of roughly 275% over the past twelve months, a significant degree of optimism is already priced into the shares. The coming quarters will prove decisive, testing Rocket Lab's ability to manage the steep costs associated with Neutron's development without compromising the profitability of its core launch business.